[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598929":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Conservatively Treated Patients",null,"Conservatively Treated Patients with Endometrial Cancer and Atypical Endometrial Hyperplasia",[13],"Procedure: Hysteroscopic Resection and Hormonal Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Hysteroscopic Resection and Hormonal Therapy","Patients underwent hysteroscopic resection of atypical endometrial hyperplasia (AEH) or grade 1-2 endometrial adenocarcinoma (EAC) using a 15 Fr mini-resectoscope. Depending on the case, the procedure included visual D\\&C or a combined technique. At the end of the procedure, a 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) was inserted. In patients with EAC G2 or poor prognostic markers (e.g., MMR deficiency), oral progestin therapy with Megestrol Acetate (160 mg daily) was added. Follow-up included hysteroscopic endometrial biopsy at 3, 6, and 12 months to assess response.",[9],[21],{"name":22,"affiliation":5,"role":23},"Ursula Catena","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"URSULA CATENA","CONTACT","+393382760021","ursula.catena@policlinicogemelli.it",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Fondazione Policlinico Universitario A. Gemelli IRCCS","RECRUITING","Roma","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],11.10642,44.99364,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":28,"phoneExt":10,"email":29},"URSULA CATENA, MD",{"type":23,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Catena Ursula","Principal Investigator","100598929","surgical-and-obstetric-outcomes-in-endometrial-adenocarcinoma-and-atypical-endometrial-hyperplasia-with-conservative-treatment-100598929",false,"NCT07077876","Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment","Surgical and Obstetric Outcomes in Patients With Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia Undergoing Conservative Treatment","CHOICE","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histological diagnosis of endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH).\n* Patients who underwent conservative treatment with hysteroscopic resection at the CLASS Hysteroscopy Center, performed by a single experienced surgeon (U.C.).\n* Patients treated conservatively due to medical contraindications to radical surgery (e.g., severe comorbidities).\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients with other known causes of infertility.\n* Patients with non-endometrioid histological subtypes of endometrial adenocarcinoma.\n* Patients under 18 years of age.\n* Patients who did not provide informed consent for participation.","FEMALE","18 Years",{"count":60,"type":61},100,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the CLASS Hysteroscopy Center of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Eligible patients include women who received hysteroscopic surgery and hormonal therapy either to preserve fertility or due to medical contraindications to standard radical surgery. Follow-up lasts 12 months.",[65,66,67,68],"Endometrial Adenocarcinoma","Endometrial Hyperplasia","Fertility Preservation","Conservative Treatment Therapy",[70,71,72,73,74,75],"Endometrial Cancer","Atypical Endometrial Hyperplasia","Fertility-Sparing Treatment","Hysteroscopy","Progestin Therapy","Reproductive Outcomes","2025-07-12",{"date":78,"type":79},"2025-07-22","ACTUAL",{"date":81,"type":79},"2025-06-20",{"date":83,"type":61},"2026-01-20",{"name":5,"class":6},1]